In a recent study published in Nature, David C. Schultz et al. demonstrated a new high-efficient therapy to fight against SARS-CoV-2, that is, combining pyrimidine biosynthetic inhibitors with antiviral nucleoside analogues. By February 10, 2022, SARS-CoV-2 has infected more than 400 million people, including more than 5.79 million deaths. Patients infected with SARS-CoV-2 usually develop mild to severe symptoms, and several patients lead to severe clinical outcomes. Although some vaccines or drugs have entered clinical practice, there is still a lack of effective antiviral therapy against the constantly changing virus.

Fuente: Sig Transduct Target Ther 7, 88 (2022)